The agreement will make Wegovy and Zepbound available to some Medicare enrollees for $245 per month, and starter doses of pill versions, once approved, for $149 monthly.

StockWatch: Cosmo Surges 40% on Baldness Candidate’s Phase III Data
Cosmo Pharmaceuticals (SIX Swiss: COSM) found itself this past week in the enviable position of attracting welcome attention from investors and other market watchers after


![A leader’s journey through profound grief and loss [PODCAST] A leader’s journey through profound grief and loss [PODCAST]](https://i0.wp.com/kevinmd.com/wp-content/uploads/The-Podcast-by-KevinMD-WideScreen-3000-px-4-scaled.jpg?w=0&resize=0,0&ssl=1)